BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32213382)

  • 1. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
    Vaclova T; Grazini U; Ward L; O'Neill D; Markovets A; Huang X; Chmielecki J; Hartmaier R; Thress KS; Smith PD; Barrett JC; Downward J; de Bruin EC
    Nat Commun; 2021 Mar; 12(1):1780. PubMed ID: 33741979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib.
    Wang H; Pan R; Zhang X; Si X; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):594-602. PubMed ID: 31943845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    Wakuda K; Yamaguchi H; Kenmotsu H; Fukuda M; Takeshita M; Suetsugu T; Kirita K; Ebi N; Hataji O; Miura S; Chibana K; Okamoto I; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
    BMC Cancer; 2020 May; 20(1):370. PubMed ID: 32357848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
    Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Gray JE; Okamoto I; Sriuranpong V; Vansteenkiste J; Imamura F; Lee JS; Pang YK; Cobo M; Kasahara K; Cheng Y; Nogami N; Cho EK; Su WC; Zhang G; Huang X; Li-Sucholeiki X; Lentrichia B; Dearden S; Jenkins S; Saggese M; Rukazenkov Y; Ramalingam SS
    Clin Cancer Res; 2019 Nov; 25(22):6644-6652. PubMed ID: 31439584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncommon
    Okuma Y; Shimokawa M; Hashimoto K; Mizutani H; Wakui H; Murakami S; Atagi S; Minato K; Seike M; Ohe Y; Kubota K;
    Future Oncol; 2022 Feb; 18(5):523-531. PubMed ID: 35034503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
    Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
    Bennouna J; Girard N; Audigier-Valette C; le Thuaut A; Gervais R; Masson P; Marcq M; Molinier O; Cortot A; Debieuvre D; Cadranel J; Lena H; Moro-Sibilot D; Chouaid C; Mennecier B; Urban T; Sagan C; Perrier L; Barlesi F; Denis MG
    Clin Lung Cancer; 2020 Jan; 21(1):e10-e14. PubMed ID: 31648999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).
    Akamatsu H; Teraoka S; Morita S; Katakami N; Tachihara M; Daga H; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2019 Jul; 20(4):e492-e494. PubMed ID: 31085043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
    Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Oki M; Tachihara M; Fujimoto D; Hayashi H; Yamaguchi K; Yamamoto S; Iwama E; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
    Lung Cancer; 2023 Mar; 177():44-50. PubMed ID: 36731290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
    Johnson M; Serra Traynor C; Vishwanathan K; Overend P; Hartmaier R; Markovets A; Chmielecki J; Mugundu GM; Barrett JC; Tomkinson H; Ramalingam SS
    Clin Pharmacol Ther; 2024 Feb; 115(2):349-360. PubMed ID: 38010260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
    Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer.
    Hori T; Yamamoto K; Ito T; Ikushima S; Omura T; Yano I
    Invest New Drugs; 2024 Jun; 42(3):281-288. PubMed ID: 38536543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC.
    Cheng ML; Lau CJ; Milan MSD; Supplee JG; Riess JW; Bradbury PA; Jänne PA; Oxnard GR; Paweletz CP
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.
    Park CK; Lee SY; Lee JC; Choi CM; Lee SY; Jang TW; Oh IJ; Kim YC
    Thorac Cancer; 2021 Feb; 12(4):444-452. PubMed ID: 33270375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
    Krug AK; Enderle D; Karlovich C; Priewasser T; Bentink S; Spiel A; Brinkmann K; Emenegger J; Grimm DG; Castellanos-Rizaldos E; Goldman JW; Sequist LV; Soria JC; Camidge DR; Gadgeel SM; Wakelee HA; Raponi M; Noerholm M; Skog J
    Ann Oncol; 2018 Mar; 29(3):700-706. PubMed ID: 29216356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
    Husain H; Melnikova VO; Kosco K; Woodward B; More S; Pingle SC; Weihe E; Park BH; Tewari M; Erlander MG; Cohen E; Lippman SM; Kurzrock R
    Clin Cancer Res; 2017 Aug; 23(16):4716-4723. PubMed ID: 28420725
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for
    Gibson AJW; Dean ML; Litt I; Box A; Cheung WY; Navani V
    Curr Oncol; 2024 Apr; 31(5):2427-2440. PubMed ID: 38785463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.